
    
      This is a single center study. This is an open label study of fluocinonide cream 0.1%
      (Vanos™) for subjects with mild to severe atopic dermatitis with an assessment of 2 to 4 on
      the Investigator Global Assessment scale (Appendix B). Up to 20 subjects age 12 and above
      will be enrolled after providing informed consent. All subjects will receive the study
      medication, fluocinonide cream 0.1% (Vanos™). Each subject will be instructed to use
      fluocinonide cream 0.1% (Vanos™) twice daily for three consecutive days (for a total of 6
      doses). The study period will last for approximately 2 weeks. Subjects will be evaluated at
      baseline and Day 2 or 3 (as needed to achieve 6 doses), day 7 and day 14 (or end of study).
      Subjects will not apply any study drug after the 6 doses.
    
  